NASDAQ:ADAG Adagene (ADAG) Stock Price, News & Analysis $2.85 -0.30 (-9.52%) (As of 05:16 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Adagene Stock (NASDAQ:ADAG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Adagene alerts:Sign Up Key Stats Today's Range$2.60▼$3.1550-Day Range$2.12▼$3.4952-Week Range$1.31▼$4.38Volume67,466 shsAverage Volume69,074 shsMarket Capitalization$126.17 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewAdagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Read More… The secret supplier behind NVIDIA, Tesla and Microsoft (Ad)The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.Click here for the ticker >>> Adagene Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks65th Percentile Overall ScoreADAG MarketRank™: Adagene scored higher than 65% of companies evaluated by MarketBeat, and ranked 423rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAdagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdagene has only been the subject of 1 research reports in the past 90 days.Read more about Adagene's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adagene are expected to decrease in the coming year, from ($0.75) to ($1.33) per share.Price to Book Value per Share RatioAdagene has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently decreased by 30.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdagene does not currently pay a dividend.Dividend GrowthAdagene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.06% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently decreased by 30.74%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.15 News SentimentAdagene has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adagene this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Adagene to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adagene insiders have not sold or bought any company stock.Percentage Held by Insiders21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.51% of the stock of Adagene is held by institutions.Read more about Adagene's insider trading history. Receive ADAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAG Stock News HeadlinesCoya stock tumbles 23% on mixed results from Alzheimer's studyOctober 29 at 6:41 PM | msn.comShort Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7%October 28 at 1:21 AM | americanbankingnews.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 31, 2024 | Porter & Company (Ad)Adagene And 2 Other US Penny Stocks To ConsiderOctober 22, 2024 | finance.yahoo.comAdagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingOctober 9, 2024 | globenewswire.comBuy Rating Affirmed on Adagene: Promising ADG126 Clinical Data and Market UnderappreciationSeptember 19, 2024 | markets.businessinsider.comAdagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)September 16, 2024 | globenewswire.comCD137 Antibodies Clinical Trials & Market Opportunity - Revolutionary CD137 Antibodies Poised to Transform Cancer Immunotherapy Landscape by 2027September 12, 2024 | finance.yahoo.comSee More Headlines ADAG Stock Analysis - Frequently Asked Questions How have ADAG shares performed this year? Adagene's stock was trading at $1.9314 at the beginning of the year. Since then, ADAG stock has increased by 47.6% and is now trading at $2.85. View the best growth stocks for 2024 here. When did Adagene IPO? Adagene (ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager. Who are Adagene's major shareholders? Adagene's top institutional investors include Catalina Capital Group LLC (0.03%). How do I buy shares of Adagene? Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adagene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adagene investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Today10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAG CUSIPN/A CIK1818838 Webwww.adagene.com Phone86-512-8777-3632FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+75.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.08 Current Ratio2.50 Quick RatioN/A Sales & Book Value Annual Sales$815,746.00 Price / Sales154.67 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book1.77Miscellaneous Outstanding Shares44,271,000Free Float34,886,000Market Cap$126.17 million OptionableNot Optionable Beta0.65 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:ADAG) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.